Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease

Journal of Clinical Lipidology

Volumn 8, Issue 1, 2014, Pages 107-116

  Toth, Peter P ^a,b   Foody, Joanne M ^c   Tomassini, Joanne E ^d   Sajjan, Shiva G ^d   Ramey, Dena R ^d   Neff, David R ^d   Tershakovec, Andrew M ^d   Hu, X Henry ^d   Tunceli, Kaan ^d  

^a CGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Ezetimibe; Goal attainment; Low density lipoprotein cholesterol; Statins; Switch

Indexed keywords

EZETIMIBE; GOAL ATTAINMENT; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; STATINS; SWITCH;

AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84893937252     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.09.009     Document Type: Article

References (43)

1. J.G. Robinson, B. Smith, N. Maheshwari, and H. Schrott Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis J Am Coll Cardiol 46 2005 1855 1862
2. C. Baigent, L. Blackwell, and J. Emberson et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. S.M. Grundy, J.I. Cleeman, and C.N. Merz et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
4. S.C. Smith Jr., J. Allen, and S.N. Blair et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372
5. G.A. Nichols, S. Nag, and W. Chan Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update Am Heart J 154 2007 554 560
6. J.M. Foody, S.G. Sajjan, and X.H. Hu et al. Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients J Clin Lipidol 4 2010 126 132
7. D.D. Waters, C. Brotons, and C.W. Chiang et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals Circulation 120 2009 28 34
8. V.G. Athyros, K. Tziomalos, A. Karagiannis, and D.P. Mikhailidis To switch (statins) or not to switch? That is the question Expert Opin Pharmacother 11 2010 2943 2946
9. D. Atar, R. Carmena, and P. Clemmensen et al. Clinical review: impact of statin substitution policies on patient outcomes Ann Med 41 2009 242 256
10. H.D. Aronow, G. Hess, J. Hill, A. Kuznik, and L.Z. Liu Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol Am J Ther 17 2010 167 175
11. D.A. Rublee, and J.P. Burke LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice Postgrad Med 122 2010 16 24
12. V.J. Willey, M.F. Bullano, N.N. Shoetan, and S.K. Gandhi Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin Curr Med Res Opin 26 2010 121 128
13. P.P. Toth, A. Catapano, J.E. Tomassini, and A.M. Tershakovec Update on the efficacy and safety of combination ezetimibe plus statin therapy Clin Lipidol 5 2010 655 684
14. A.L. Catapano, P.P. Toth, J.E. Tomassini, and A.M. Tershakovec The efficacy and safety of ezetimibe co-administered with statin therapy in various patient groups Clin Lipidol 8 2013 13 41
15. Crestor (rosuvastatin calcium) tablets [package insert] 2012 AstraZeneca Wilmington, DE
16. Zocor (simvastatin) tablets [package insert] 2010 Merck & Co Inc Whitehouse Station, NJ
17. Pravachol [package insert] 2011 Bristol-Myers Squibb Co Princeton, NJ
18. D.J. Maron, S. Fazio, and M.F. Linton Current perspectives on statins Circulation 101 2000 207 213
19. Mevacor [product insert] 2010 Merck & Co Inc Whitehouse Station, NJ
20. LESCOL/LESCOL XL (fluvastatin) [package insert] 2011 Novartis Pharmaceuticals Corporation East Hanover, NJ
21. Lipitor (atorvastatin calcium) tablets [package insert] 2012 Pfizer, Inc New York, NY
22. P.P. Toth, C.M. Ballantyne, and M.H. Davidson et al. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction J Clin Lipidol 6 2012 180 191
23. A.B. Kauffman, K.L. Olson, M.L. Youngblood, E.B. Zadvorny, T. Delate, and J.A. Merenich Attainment of low-density lipoprotein cholesterol goals in coronary artery disease J Clin Lipidol 4 2010 173 180
24. D. Kitkungvan, N.M. Lynn Fillipon, S.S. Dani, and B.C. Downey Low-density lipoprotein cholesterol target achievement in patients at high risk for coronary heart disease J Clin Lipidol 4 2010 293 297
25. S.S. Nag, G.W. Daniel, and M.F. Bullano et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO J Manag Care Pharm 13 2007 652 663
26. B.A. Steinberg, D.L. Bhatt, and S. Mehta et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease Am Heart J 156 2008 719 727
27. W.C. Roberts The rule of 5 and the rule of 7 in lipid-lowering by statin drugs Am J Cardiol 80 1997 106 107
28. K. Tunceli, S.G. Sajjan, and D.R. Ramey et al. Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients J Clin Lipidol 4 2010 491 500
29. R. Butler, and J. Wainwright Cholesterol lowering in patients with CHD and metabolic syndrome Lancet 369 2007 27
30. F. Colivicchi, M. Tubaro, and M. Santini Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes Int J Cardiol 152 2011 56 60
31. B. Phillips, C. Roberts, A.E. Rudolph, S. Morant, F. Aziz, and C. O'Regan Switching statins: the impact on patient outcomes Br J Cardiol 14 2007 280 285
32. R.J. Willke, S. Zhou, and R.A. Vogel Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience Curr Med Res Opin 24 2008 2873 2882
33. R.L. Ohsfeldt, S.K. Gandhi, K.M. Fox, and J.M. McKenney Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications Value Health 11 2008 1061 1069
34. P.S. Chan, B.K. Nallamothu, H.S. Gurm, R.A. Hayward, and S. Vijan Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease Circulation 115 2007 2398 2409
35. P. Lindgren, J. Graff, A.G. Olsson, T.J. Pedersen, and B. Jonsson Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Eur Heart J 28 2007 1448 1453
36. R.J. Straka, M. Mamdani, and J. Damen et al. Economic impacts attributable to the early clinical benefit of atorvastatin therapy-a US managed care perspective Curr Med Res Opin 23 2007 1517 1529
37. J. Reckless, G. Davies, K. Tunceli, X.H. Hu, and P. Brudi Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study Value Health 13 2010 726 734
38. A.L. Catapano, Z. Reiner, and G. De Backer et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
39. D.G. Karalis, B. Victor, L. Ahedor, and L. Liu Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients Cholesterol 2012 2012 861924
40. C. Baigent, M.J. Landray, and C. Reith et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
41. I. Holme, K. Boman, and P. Brudi et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial Am J Cardiol 105 2010 1802 1808
42. A.B. Rossebo, T.R. Pedersen, and K. Boman et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 359 2008 1343 1356
43. R.M. Califf, Y. Lokhnygina, and C.P. Cannon et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J 159 2010 705 709